Benchmark Holdings (BMK)

Sector:

Pharma and Biotech

35.60p
   
  • Change Today:
    -3.40p
  • 52 Week High: 48.00p
  • 52 Week Low: 34.00p
  • Currency: UK Pounds
  • Shares Issued: 739.79m
  • Volume: 118,205
  • Market Cap: £263.37m
  • Beta: 0.48

Benchmark revenues rise in third quarter

By Josh White

Date: Thursday 25 Aug 2022

LONDON (ShareCast) - (Sharecast News) - Aquaculture biotechnology company Benchmark reported a 28% improvement in third-quarter revenues on Thursday, to £36.3m.
The AIM-traded firm said its genetics operation delivered an "excellent performance", with revenues up 50% year-on-year thanks to higher sales of salmon eggs and harvest revenues. Year-to-date revenues in genetics were 29% firmer.

Advanced nutrition reported revenues 5% above the prior year, in line with its anticipated seasonal pattern, while year-to-date revenues were up 15%.

Health division revenues surged 213%, driven by the 'Ectosan Vet' and 'CleanTreat' products, with revenues for the year to date up 308%.

Adjusted EBITDA, excluding fair value movements from biological assets, were ahead 26% in the third quarter as a result of higher revenues, higher asset utilisation and cost discipline.

Benchmark reported an adjusted EBITDA margin of 14% for the period.

For the year-to-date, group revenues were 32% higher, and adjusted EBITDA excluding fair value movements from biological assets was 99% firmer year-on-year.

The board reported an increase in its adjusted EBITDA margin to 17%, from 11% for the first nine months of 2021, which it described as "notable" in a global inflationary environment.

Its operating loss expanded due to depreciation and amortisation from 'CleanTreat' units and leased vessels, and the first amortisation of 'Ectosan Vet' and 'CleanTreat' development costs.

The statutory loss before tax widened due to a "significant" £5.9m increase in net finance costs, which the company put down to a £3.1m foreign exchange loss mainly driven by the translation of dollar-denominated loan balances, abd a £2.3m loss in the fair value of financial instruments related to hedging of its Norwegian krone bond.

Benchmark said the year-to-date impact of those caused a negative movement of £10.7m, increasing net finance costs to £10m for the year thus far.

The company had cash of £37.3m and liquidity of £50.3m as at 23 August, with net debt, excluding lease liabilities, totalling £59.3m.

"The third quarter represents a continuation of the operational and financial progress reported consistently by Benchmark over the quarters following the 2020 restructuring," said chief executive officer Trond Williksen.

"We continue our dedicated work to realise the potential of the well invested and well positioned platform that Benchmark has become."

Williksen said the company was "excited" about the development of a new configuration and business model for 'CleanTreat', which although reducing its growth rate for the next year, increased the company's confidence in the solution and enhances its long-term prospects.

"Overall, we expect to continue to deliver further underlying progress in the coming quarters, with the aim of becoming a profitable company supporting the global aquaculture industry with sustainable solutions."

At 0945 BST, shares in Benchmark Holdings were up 0.73% at 41.35p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

BMK Market Data

Currency UK Pounds
Share Price 35.60p
Change Today -3.40p
% Change -8.72 %
52 Week High 48.00p
52 Week Low 34.00p
Volume 118,205
Shares Issued 739.79m
Market Cap £263.37m
Beta 0.48

BMK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
19.67% below the market average19.67% below the market average19.67% below the market average19.67% below the market average19.67% below the market average
32.00% above the sector average32.00% above the sector average32.00% above the sector average32.00% above the sector average32.00% above the sector average
Price Trend
32.77% below the market average32.77% below the market average32.77% below the market average32.77% below the market average32.77% below the market average
30.61% above the sector average30.61% above the sector average30.61% above the sector average30.61% above the sector average30.61% above the sector average
Income Not Available
Growth
10.03% above the market average10.03% above the market average10.03% above the market average10.03% above the market average10.03% above the market average
17.65% above the sector average17.65% above the sector average17.65% above the sector average17.65% above the sector average17.65% above the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

BMK Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
13:45 3 @ 35.64p
12:40 44 @ 36.00p
11:41 5,682 @ 36.00p
11:41 6,318 @ 36.00p
11:38 7,236 @ 35.61p

BMK Key Personnel

Chair Peter George
CFO Septima Maguire
CEO Trond Williksen

Top of Page